Motso et al. reasoned that novel β2AR agonists that efficaciously stimulate glucose uptake while only weakly activating the Gs/cAMP/PKA signaling axis could serve as potential drug candidates to treat type 2 diabetes and obesity. Here, ADRB2 is linked to obesity disorder.